PRDM1 and neoplasm: However, genetic deletion of PRDM1 alone resulted in only marginal enhancement of CAR T-cell efficacy against B-cell leukemia and completely failed to rescue CAR+ tumor-infiltrating lymphocyte (TIL) function in animal models of high tumor burden.